(BCSF) Bain Capital Specialty - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US05684B1070
Stock: Senior Debt, Unitranche, Mezzanine, Junior Securities, Secondary Debt
Total Rating 17
Risk 59
Buy Signal -1.23
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 12.29% |
| Yield on Cost 5y | 23.14% |
| Yield CAGR 5y | 24.55% |
| Payout Consistency | 93.8% |
| Payout Ratio | 110.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.8% |
| Relative Tail Risk | 4.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.81 |
| Alpha | -29.94 |
| Character TTM | |
|---|---|
| Beta | 0.756 |
| Beta Downside | 0.819 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.91% |
| CAGR/Max DD | 0.49 |
Description: BCSF Bain Capital Specialty January 20, 2026
Bain Capital Specialty Finance, Inc. (NYSE: BCSF) operates as a business-development company that provides direct senior-secured loans to U.S. middle-market firms, typically targeting companies with EBITDA of $10 million–$150 million. Its investment scope includes first- and second-lien senior debt, stretch senior, unitranche, mezzanine, junior securities, and secondary purchases of existing loan portfolios.
Recent filings show BCSF’s loan portfolio averages a weighted-average interest rate of roughly 8.5%, with a net interest margin near 3.2% and a loan-to-value ratio around 65%, reflecting a conservative credit profile. The firm’s earnings have been sensitive to the Fed’s policy cycle: higher rates boost yield spreads on senior debt but also increase credit-risk premiums, while a slowdown in middle-market M&A activity can dampen new loan origination volumes.
For a deeper quantitative view, you might explore ValueRay’s analyst tools to benchmark BCSF’s valuation multiples against peers and track its credit-quality trends over time.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 93.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.98 > 1.0 |
| NWC/Revenue: 1.08% < 20% (prev 15.65%; Δ -14.57% < -1%) |
| CFO/TA 0.03 > 3% & CFO 87.8m > Net Income 93.1m |
| Net Debt (-67.0m) to EBITDA (97.3m): -0.69 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.9m) vs 12m ago 0.47% < -2% |
| Gross Margin: 57.37% > 18% (prev 0.67%; Δ 5670 % > 0.5%) |
| Asset Turnover: 7.30% > 50% (prev 8.64%; Δ -1.34% > 0%) |
| Interest Coverage Ratio: 1.19 > 6 (EBITDA TTM 97.3m / Interest Expense TTM 81.9m) |
Altman Z'' 0.19
| A: 0.00 (Total Current Assets 104.3m - Total Current Liabilities 102.2m) / Total Assets 2.72b |
| B: -0.01 (Retained Earnings -35.6m / Total Assets 2.72b) |
| C: 0.04 (EBIT TTM 97.3m / Avg Total Assets 2.63b) |
| D: -0.02 (Book Value of Equity -35.5m / Total Liabilities 1.59b) |
| Altman-Z'' Score: 0.19 = B |
What is the price of BCSF shares?
As of February 08, 2026, the stock is trading at USD 13.11 with a total of 547,872 shares traded.
Over the past week, the price has changed by -0.46%, over one month by -6.49%, over three months by +0.25% and over the past year by -17.06%.
Over the past week, the price has changed by -0.46%, over one month by -6.49%, over three months by +0.25% and over the past year by -17.06%.
Is BCSF a buy, sell or hold?
Bain Capital Specialty has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold BCSF.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BCSF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.8 | 13.1% |
| Analysts Target Price | 14.8 | 13.1% |
| ValueRay Target Price | 16.2 | 23.5% |
BCSF Fundamental Data Overview February 03, 2026
P/E Trailing = 9.1458
P/E Forward = 10.3842
P/S = 3.0693
P/B = 0.7582
P/EG = 1.0697
Revenue TTM = 192.1m USD
EBIT TTM = 97.3m USD
EBITDA TTM = 97.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 1.39b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -67.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.18b USD (854.3m + Debt 1.39b - CCE 67.0m)
Interest Coverage Ratio = 1.19 (Ebit TTM 97.3m / Interest Expense TTM 81.9m)
EV/FCF = 24.80x (Enterprise Value 2.18b / FCF TTM 87.8m)
FCF Yield = 4.03% (FCF TTM 87.8m / Enterprise Value 2.18b)
FCF Margin = 45.72% (FCF TTM 87.8m / Revenue TTM 192.1m)
Net Margin = 48.48% (Net Income TTM 93.1m / Revenue TTM 192.1m)
Gross Margin = 57.37% ((Revenue TTM 192.1m - Cost of Revenue TTM 81.9m) / Revenue TTM)
Gross Margin QoQ = 52.41% (prev 55.92%)
Tobins Q-Ratio = 0.80 (Enterprise Value 2.18b / Total Assets 2.72b)
Interest Expense / Debt = 1.46% (Interest Expense 20.3m / Debt 1.39b)
Taxrate = 4.11% (801.0k / 19.5m)
NOPAT = 93.3m (EBIT 97.3m * (1 - 4.11%))
Current Ratio = 1.02 (Total Current Assets 104.3m / Total Current Liabilities 102.2m)
Debt / Equity = 1.23 (Debt 1.39b / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = -0.69 (Net Debt -67.0m / EBITDA 97.3m)
Debt / FCF = -0.76 (Net Debt -67.0m / FCF TTM 87.8m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.54% (Net Income 93.1m / Total Assets 2.72b)
RoE = 8.18% (Net Income TTM 93.1m / Total Stockholder Equity 1.14b)
RoCE = 3.72% (EBIT 97.3m / Capital Employed (Total Assets 2.72b - Current Liab 102.2m))
RoIC = 3.57% (NOPAT 93.3m / Invested Capital 2.61b)
WACC = 4.18% (E(854.3m)/V(2.24b) * Re(8.70%) + D(1.39b)/V(2.24b) * Rd(1.46%) * (1-Tc(0.04)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.24%
[DCF Debug] Terminal Value 86.85% ; FCFF base≈105.7m ; Y1≈111.6m ; Y5≈131.5m
Fair Price DCF = 61.16 (EV 3.90b - Net Debt -67.0m = Equity 3.97b / Shares 64.9m; r=5.90% [WACC]; 5y FCF grow 6.05% → 2.90% )
EPS Correlation: -27.58 | EPS CAGR: -42.04% | SUE: -4.0 | # QB: 0
Revenue Correlation: 36.75 | Revenue CAGR: 1.26% | SUE: -0.99 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.43 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.65 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-12.5% | Growth Revenue=-6.0%
P/E Forward = 10.3842
P/S = 3.0693
P/B = 0.7582
P/EG = 1.0697
Revenue TTM = 192.1m USD
EBIT TTM = 97.3m USD
EBITDA TTM = 97.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 1.39b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -67.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.18b USD (854.3m + Debt 1.39b - CCE 67.0m)
Interest Coverage Ratio = 1.19 (Ebit TTM 97.3m / Interest Expense TTM 81.9m)
EV/FCF = 24.80x (Enterprise Value 2.18b / FCF TTM 87.8m)
FCF Yield = 4.03% (FCF TTM 87.8m / Enterprise Value 2.18b)
FCF Margin = 45.72% (FCF TTM 87.8m / Revenue TTM 192.1m)
Net Margin = 48.48% (Net Income TTM 93.1m / Revenue TTM 192.1m)
Gross Margin = 57.37% ((Revenue TTM 192.1m - Cost of Revenue TTM 81.9m) / Revenue TTM)
Gross Margin QoQ = 52.41% (prev 55.92%)
Tobins Q-Ratio = 0.80 (Enterprise Value 2.18b / Total Assets 2.72b)
Interest Expense / Debt = 1.46% (Interest Expense 20.3m / Debt 1.39b)
Taxrate = 4.11% (801.0k / 19.5m)
NOPAT = 93.3m (EBIT 97.3m * (1 - 4.11%))
Current Ratio = 1.02 (Total Current Assets 104.3m / Total Current Liabilities 102.2m)
Debt / Equity = 1.23 (Debt 1.39b / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = -0.69 (Net Debt -67.0m / EBITDA 97.3m)
Debt / FCF = -0.76 (Net Debt -67.0m / FCF TTM 87.8m)
Total Stockholder Equity = 1.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.54% (Net Income 93.1m / Total Assets 2.72b)
RoE = 8.18% (Net Income TTM 93.1m / Total Stockholder Equity 1.14b)
RoCE = 3.72% (EBIT 97.3m / Capital Employed (Total Assets 2.72b - Current Liab 102.2m))
RoIC = 3.57% (NOPAT 93.3m / Invested Capital 2.61b)
WACC = 4.18% (E(854.3m)/V(2.24b) * Re(8.70%) + D(1.39b)/V(2.24b) * Rd(1.46%) * (1-Tc(0.04)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.24%
[DCF Debug] Terminal Value 86.85% ; FCFF base≈105.7m ; Y1≈111.6m ; Y5≈131.5m
Fair Price DCF = 61.16 (EV 3.90b - Net Debt -67.0m = Equity 3.97b / Shares 64.9m; r=5.90% [WACC]; 5y FCF grow 6.05% → 2.90% )
EPS Correlation: -27.58 | EPS CAGR: -42.04% | SUE: -4.0 | # QB: 0
Revenue Correlation: 36.75 | Revenue CAGR: 1.26% | SUE: -0.99 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.43 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=1.65 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-12.5% | Growth Revenue=-6.0%